Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Peter G. Rose, MD
The Cleveland Clinic
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Holden Comprehensive Cancer Center at the University of Iowa
Iowa City, Iowa, United States
- Mercy Medical Center, Inc.
Baltimore, Maryland, United States
- Cooper Hospital/university Medical Center
Camden, New Jersey, United States
- Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, United States
- Ireland Cancer Center
Cleveland, Ohio, United States
- Arthur G. James Cancer Hospital - Ohio State University
Columbus, Ohio, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 1999
- Primary completion
- 30 Apr 2006
- Completion
- —
- Last update posted
- 27 May 2013
- Registered enrollment
- 24
- Registry id
- NCT00003967
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.